The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About
    • Mission & Activities
    • Directors and Officers
    • Marketing & Promotions
    • The Antibody Society’s Committees
      • Meetings Committee
      • AIRR Community Working Groups & Sub-Committees
    • Sponsors & Partners
  • Society meetings
    • Computational Antibody Discovery: State of the Art
      • Computational Antibody Discovery Symposium Participants
    • Harnessing Cytokines for Cancer Immunotherapy Symposium
    • Biopharmaceutical Informatics Symposium
    • Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium
    • Emerging Immunotherapeutics for Ovarian Cancer Symposium
    • AIRR Community Meetings
    • Antibody Engineering & Therapeutics (US) 2024
      • 2022 Antibody Engineering & Therapeutics
      • 2020 Antibody Engineering & Therapeutics
      • 2019 Antibody Engineering & Therapeutics
      • 2018 Antibody Engineering & Therapeutics
      • What is INN a Name?
        • INN issue updates
    • Antibody Engineering & Therapeutics Europe 10 – 12 June, 2025 | Congress Center, Basel Switzerland.
      • Scientific Advisors, Antibody Engineering & Therapeutics Europe
    • FOCIS Symposia
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Members only
    • Login
    • Note to members
    • Member discount codes
    • 2025 Calendar of Events
    • James S. Huston Antibody Science Talent Award
      • 2024 James S. Huston Antibody Science Talent Award Recipient
      • 2023 James S. Huston Antibody Science Talent Award Recipient
      • 2022 James S. Huston Antibody Science Talent Award Recipient
      • 2021 James S. Huston Antibody Science Talent Award Recipient
      • 2020 James S. Huston Antibody Science Talent Award Recipient
      • Huston Award submission guidelines
    • Research Competitions
      • Research Competition Winners
    • Science Writing Competition
      • Science Writing Competition Winners
    • Imaging Competition
      • Imaging Calendar Competition winners
        • The Antibody Society 2025 Calendar
        • The Antibody Society 2024 Calendar
    • Antibodies in early-stage studies
    • Presentations
  • Upcoming meetings in 2025
  • Web Resources
    • Society Publications
    • Antibody News
    • Antibody News Podcast
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies in late-stage clinical studies
    • Research Resources
    • Education Resources
  • Career Center
    • Career Shorts
  • Learning Center
    • Upcoming Webinars in 2025
    • The Antibody Series Lectures
    • Antibody Discovery & Development
    • Adaptive Immune Receptor Repertoires
    • Antibodies to Watch
    • Commercializing Antibody Therapeutics
    • Antibody Validation
      • 4th International Antibody Validation Meeting, Sep 2023
    • Snakebite antivenoms: Global challenges and progress toward recombinant antibody therapeutics

August 20, 2024 by Joshua Dorai


Announcing Leadership Changes and New Opportunities at The Antibody Society.


We are pleased to announce that Dr. Janice Reichert, who has served as our Chief Operating Officer, will be transitioning to a new role as Director of Business Intelligence. Janice’s leadership has been crucial to our success, and we are confident that she will continue to drive our mission forward in this new capacity.

Dr. Janice Reichert is an internationally recognized expert in the development of antibody therapeutics. She has been affiliated with The Antibody Society since 2010, serving on the Society’s Board of Directors and various committees, including as Executive Director and most recently as Chief Operating Officer. She is now transitioning to the role of Director of Business Intelligence.

Dr. Reichert created mAbs, a peer-reviewed, PubMed-indexed biomedical journal focusing on antibody research and development and has served as Editor-in-Chief since its inaugural publication in 2009. She has published extensively on development trends for antibody therapeutics and is particularly well known for creating the annual “Antibodies to Watch” articles, which have collectively been viewed nearly 290,000 times. Dr. Reichert has also presented her research at conferences worldwide. She received her Ph.D. in Chemistry from the University of Pennsylvania and completed her post-doctoral training at Harvard Medical School.

We wish Janice all the best in her new role!


Join Our Growing Team!


As we continue to expand, we are seeking a talented and experienced Business Manager to oversee all aspects of our organization’s financial and operational functions. If you have a strong background in business management and are passionate about joining our mission to enhance knowledge and understanding through information sharing and collaboration in the field of antibody research and development, we encourage you to apply.

Please send your resume to jobs@antibodysociety.org

For more information about the role, please refer to the detailed job description provided below.

  • LinkedIn
  • The Antibody Society Career Center

Looking Ahead.


We will be announcing additional new roles in the coming months. Be sure to watch this space for more opportunities to join our team.

Thank you for being a part of our community!

https://www.antibodysociety.org/the-antibody-society-org-news/18648/

Filed Under: The Antibody Society Org News

AIRR-C Meeting VII: A Landmark in AIRR Research!

July 14, 2024 by Pam Borghardt

The AIRR-C VII Meeting, held from June 3-6, 2024, at the Faculty of Engineering, University of Porto, Portugal, was a triumph, highlighting the latest in AIRR research. We delved into “Fundamental Immunological Processes and Human Diseases” through dedicated and groundbreaking discussions. Challenge sessions included Germline Gene Diversity where we explored interindividual variability in AIRRs with major implications for disease and vaccine prediction and Machine Learning Approaches which showcased AIRRs’ potential in predicting disease outcomes and discovering new therapeutic targets. 

Key Highlights

The success of AIRR-C VII was bolstered by the generous support of our 19 sponsors and partners, whose contributions were instrumental. We extend our heartfelt thanks to all who supported us. The event drew a diverse global audience with 182 in-person attendees and 31 remote participants from 26 countries, marking an increase from 2022. Our exceptional program featured 16 invited speakers, 10 contributed talks, 96 research posters, 11 Working Group and Sub-Committee posters, and a dynamic mix of sessions including 10 lightning demos and 9 deep dive tutorials. Participants engaged in hands-on, one-hour “deep dive” tutorials and short 10-minute “lightning” demonstrations of innovative software and tools, enhancing their technical skills and knowledge.

Early career researchers and students actively participated in career development activities alongside the scientific program. “Networking is in the AIRR” featured a speed networking event connecting early career scientists with established AIRR researchers, fostering invaluable connections across sectors and research areas. A career development panel discussion offered insights into diverse career paths within AIRR research, complementing the scientific sessions and providing opportunities for direct engagement with experts.

As part of the Industry Networking Reception, a special “hot topics in the field” round table session provided a unique opportunity for industry partners and scientific researchers to engage in exciting discussions. Moderated by pairs of AIRR-C Working Group Co-leaders and Industry Partners, these sessions focused on future needs and challenges in key areas such as “Antibody Discovery,” “AIRR-seq epitope/antigen annotation,” “Datasets and applications/tools for mining the repertoire,” “Biological Standards/Controls/Methods,” and “Data sharing & data standards for AIRR analysis and software.” The goal of these discussions was to gather input and ideas to shape the future of AIRR research.

Looking Ahead

AIRR-C VII has set a new standard for excellence. We eagerly anticipate the AIRR-C VIII meeting in 2026, where we will continue driving the exciting advancements in immunogenetics.

For more information, visit [Event Website] or contact us at [Contact Information] or follow us at #AIRRC8.

Filed Under: AIRR Community

FDA approves Kisunla™ (donanemab-azbt) for Alzheimer’s disease

July 2, 2024 by Janice Reichert

On July 2, 2024, the U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion) for adults with early symptomatic Alzheimer’s disease (AD) and people with the mild dementia stage of AD, with confirmed amyloid pathology. Donanemab (LY3002813) is a humanized IgG1k monoclonal antibody that targets Ab(p3-42), a pyroglutamate form of amyloid beta that is aggregated in amyloid plaques. Donanemab was granted Breakthrough Therapy designation by FDA for the treatment of AD.

FDA’s approval was based in part on results from the TRAILBLAZER-ALZ 2 Phase 3 study in which 1736 patients with early symptomatic AD with amyloid and low/medium or high tau pathology were randomized 1:1 to receive IV donanemab (n=860) or placebo (n=874) Q4W for 72 weeks. [1] Trial participants were analyzed over 18 months in two groupings: one group who was less advanced in their disease (those with low to medium levels of tau protein) and the overall population. Treatment with Kisunla significantly slowed clinical decline in both groups, with people who were the least advanced in the disease experiencing the strongest results with Kisunla.

  1. Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512-527. doi: 10.1001/jama.2023.13239.

Filed Under: Food and Drug Administration Tagged With: Alzheimer's, donanemab

Monday, June 3rd is the Big Day!

June 2, 2024 by Edel Aron

AIRR-C Meeting VII – Learnings and Perspectives is starting this Monday, June 3rd, at the Faculty of Engineering, University of Porto, in Porto, Portugal. This meeting is the regular main event of the AIRR Community and allows participants (both in-person and virtual)to enjoy a variety of scientific presentations, discussions, and poster sessions to stay up-to-date with the most recent developments in the field. It is also a great opportunity to engage with colleagues and industry sponsors, and to help early career researchers such as graduate students and post-docs learn more about possible opportunities. A huge thank you to all our sponsors who make this event possible. Your support is invaluable and greatly appreciated!

Check out the full agenda and more details on the meeting page: https://tinyurl.com/airrcmeeting7.

Use the hashtag #AIRRC7 in social media to follow and share content about AIRR-C Meeting VII.

AIRR Community Meeting VII 2024 Sponsors Infographic

Filed Under: AIRR Community Tagged With: Adaptive Immune Receptor Repertoire Community, Meetings

Congratulations to the winners of the 2024 Science Writing Competition!

May 30, 2024 by Silvia Crescioli

The Antibody Society offers our student and post-doc members a chance to grow their writing skills through a Science Writing Competition. This competition is organized and managed by the Society’s Communication & Membership Committee.

Entrants submitted essays of 1200 – 1500 words on a topic related to antibody research that were evaluated by our panel of judges based on: originality, structure of the essay, and presentation (clarity and creativity).

University student winner:
Igor García Atutxa (Universidad Católica San Antonio de Murcia, Murcia, Spain)

Essay title: “Dark Times in Microscopic Earth: The Immunological Epic Against the Dark Forces of Infection”

 
 

Secondary school student winner:
William Levy (Seabury Hall College Prep School, Maui, HI, USA)

Essay title: “Including Antibodies in Cancer Treatment”

 

 

Congratulations to the winners and thanks to everyone who participated! 

The next Science Writing Competition opens in March 2025.

Filed Under: Competition Tagged With: antibodies, competition, mAbs

« Previous Page
Next Page »

mabs

mabs

The Official Journal of The Antibody Society

Career Center

Our Career Center is a premier resource to connect highly qualified talent with matching career opportunities. Visit for details on over 800 jobs!

Featured Jobs

No jobs available.
View All JobsPost a Job
Powered by

AIRR Community

AIRR Community

The Adaptive Immune Receptor Repertoire Community is a research-driven group organizing around the use of high-throughput sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Recent Posts

  • Zooming into the Community III — A Milestone Virtual Gathering! June 3, 2025
  • Register now for the June 26th AIRR Community Seminar Series June 3, 2025
  • Zooming into the Community III Starts Tomorrow! May 20, 2025

Archives

Follow us online

  • Email
  • LinkedIn
  • Twitter
  • YouTube
  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members only
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals